What happened
Zio XT, from iRhythm Technologies, is a single-lead ECG patch worn for up to 14 days. Its ZEUS software uses a fixed deep neural network to flag arrhythmias, and company technicians check the results before a report goes to the clinician. The National Institute for Health and Care Excellence (NICE) recommended Zio XT in guidance published on 1 December 2020. The committee concluded that Zio XT increases diagnostic yield compared with 24-hour Holter monitoring. In three of four comparative studies, the yield over total wear time was higher. The evidence included a UK randomized trial in 116 people after stroke or transient ischemic attack. Clinical experts credited the gain mainly to the longer wear time. NICE's assessors found that the network was trained on a large dataset and raised no concerns. NICE judged that Zio XT was likely to be cost neutral or cost saving and asked NHS users to collect more evidence. No study showed that the higher yield improves clinical outcomes.
Sources
-
Assessment report, by authors with no tie to the system.
Evidence shows that Zio XT is convenient and easy to wear, with an improved diagnostic yield (a measure of how many people with cardiac arrhythmia are diagnosed) compared with standard 24‑hour Holter monitoring. The technology is likely to be cost neutral or cost saving compared with 24‑hour Holter monitoring, but more evidence is needed.
-
Assessment report, by authors with no tie to the system.
National Institute for Health and Care Excellence. HTG562, section 3: Evidence. 1 December 2020.
During consultation, KiTec EAC reviewed the artificial intelligence in Zio XT's ZEUS software. It noted that the algorithm to detect arrythmia uses a fixed deep neural network (a computational model made up of multiple processing layers) and that the training of the system is adequate.
Details
AI system
- Workflow
-
The patch recorded a continuous single-lead ECG for up to 14 days. Company cardiographic technicians checked the algorithm's findings before the report went to the clinician.
Follow-up
- Conditions for replication
-
People wear the patch for most of the scheduled days. Outpatient appointments after a negative result stay uncommon, as in the cost scenarios that NICE favored.
Entry details
- Sector
-
Healthcare (cardiology).
- Purpose
-
IRhythm Technologies built Zio XT to record a person's heart rhythm for up to 14 days and flag arrhythmias in a report for the clinician.
Not yet checked: model, release, provider, role, configuration, inputs and outputs, autonomy, human oversight, AI contribution, beneficiaries, reach, distribution and access, duration, every measurement question, every money question, ownership and control, dependencies, cross-border connections, geopolitical implications, replication attempts, availability, institutional decision, grounds, action and result, success criterion, every evidence question, observed or intended, alternative assessments, related entries, other identifiers, category mappings.
Cite this record
Peter H. Vartanian. (2026). Zio XT patch catches more heart rhythm problems than a 24-hour Holter (AIBD-0735). Artificial Intelligence Benefits Database, edition of 31 October 2026. https://petervartanian.xyz/aibd/records/AIBD-0735.html (archived at https://doi.org/10.7910/DVN/AADSII, version 4.0)